Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Ulixertinib (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 16 Mar 2017 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2018.
- 14 Feb 2017 Planned End Date changed from 1 Mar 2020 to 31 Dec 2020.